DALLAS, TX – 03/10/2024 – (SeaPRwire) – Adnexus Biotechnologies Inc., a trailblazer in the realm of biotechnology, is making waves with the launch of its groundbreaking Artificial Intelligence (AI) platform, Sutra
. Positioned at the intersection of cutting-edge AI and biotechnology, Sutra represents the company’s most ambitious initiative yet in revolutionizing early drug discovery. The platform’s exceptional ability to streamline the identification of therapeutic targets marks a critical step forward for the entire pharmaceutical industry, which has long faced bottlenecks in the development and validation of new treatments.
Sutra is more than a technological breakthrough—it is a promise of efficiency and accuracy in a field often fraught with uncertainty. Leveraging its powerful AI-driven algorithms, the platform has successfully validated numerous scientific hypotheses that have been in the making for years. In mere weeks, Sutra was able to identify new targets for monoclonal antibodies, a process that traditionally takes years of exhaustive research. This achievement did not go unnoticed, with independent collaborators confirming the immense potential of these findings. The identification of a significant target within mitochondrial metabolism related to oncology highlights the platform’s far-reaching implications, particularly in areas such as cancer research, which has been desperate for such advancements. With these discoveries, Adnexus has expanded its already extensive intellectual property (IP) portfolio, which includes patents, trademarks, and trade secrets, further solidifying the company’s competitive edge in the biotech landscape.
Adnexus Biotechnologies’ pioneering use of AI extends beyond traditional applications. Sutra is equipped with state-of-the-art structure prediction algorithms capable of not only designing small molecules but also optimizing the architecture of antibodies and other vital proteins. This technology could dramatically enhance the effectiveness of drug therapies across multiple fields. The platform’s ability to repurpose existing drug molecules offers a cost-effective, time-saving alternative to traditional drug development, providing the potential to fast-track life-saving treatments to market.
A particularly impressive feature of the Sutra platform is its application in pandemic preparedness. With an expansive database of 19 viruses, Sutra can anticipate and even help to prevent future pandemics by identifying neutralizable epitopes on viruses. This process allows the platform to enhance the efficacy of existing therapies and discover new drugs that could serve as critical solutions in global healthcare crises. The platform’s access to a curated library of 8 million molecules also underscores its unparalleled capacity for drug discovery.
In addition to its core competencies, the Sutra team is venturing into the realm of neurodegenerative disease research by leveraging microbiome samples to identify new biomarkers. The potential for breakthroughs in diseases such as Alzheimer’s and Parkinson’s is now within reach, thanks to these innovations. The ongoing collaboration between AI technology and clinical research holds promise for solving some of the most pressing medical challenges of our time.
A notable aspect of Adnexus’ strategy is its dedication to advancing drug repurposing, which leverages existing compounds to uncover new therapeutic applications. Traditionally, this is a time-intensive process, but with AI, it becomes significantly faster and more accurate. The Sutra platform can evaluate existing databases and pinpoint promising compounds for repurposing in a fraction of the time that conventional methods would require. This approach is especially useful for developing combination therapies, which offer enhanced effectiveness compared to standalone treatments.
CEO Gaurav Chandra emphasized the transformative potential of these innovations: “The integration of AI into our drug discovery processes is not just a reflection of current trends but a necessity for overcoming long-standing challenges in the biotech industry. Our AI-empowered platform is pushing the boundaries of what is possible in drug discovery and infectious disease research.” Dr. Chandra also highlighted the company’s ambition to introduce a Software-as-a-Service (SAAS) and Data-as-a-Service (DAAS) model for their AI platform by next year. This expansion into new revenue-generating streams reflects Adnexus’ commitment to financial stability and long-term growth, offering its expertise to academic institutions and biotechnology firms alike.
Further bolstering its market presence, Adnexus Biotechnologies has signed a Letter of Intent with 1606 Corp (OTC PINK
), an AI technology firm, marking the beginning of a strategic investment relationship. This move aligns with Adnexus’ broader objective to remain at the forefront of AI-driven drug discovery and strengthen its position within the fast-evolving biotech sector.
Adnexus Biotechnologies Inc. remains at the vanguard of technological innovation within the biotech industry. With its AI-powered Sutra platform leading the charge, the company is set to redefine the landscape of drug discovery, infectious disease research, and therapeutic development.
Industry Overview:
The global AI-driven drug discovery market has seen exponential growth, valued at USD 1.5 billion in 2023 and expected to maintain a robust Compound Annual Growth Rate (CAGR) of 29.7% from 2024 to 2030. This surge is largely driven by the increasing demand for new therapeutic drugs, along with advancements in AI technologies such as machine learning and deep learning. These innovations are playing a pivotal role across various stages of drug development, including compound screening and clinical trial success predictions. With the influx of startups focused on AI-powered drug discovery and the rising tide of investments in this space, the market is poised for unprecedented expansion.
Forward-Looking Statements:
This press release contains forward-looking statements based on projections and expectations regarding future business developments. These statements are subject to risks and uncertainties and are identified by terms like “may,” “should,” “anticipates,” and “intends.” While based on reasonable assumptions, actual results may differ from expectations. Adnexus Biotechnologies Inc. is under no obligation to update any forward-looking statements except as required by law.
SOURCE: Adnexus Biotechnologies Inc.
by Arrow123
The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith.
Sectors: Top Story, Corporate News
SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi …
source https://newsroom.seaprwire.com/technologies/adnexus-biotechnologies-unveils-cutting-edge-ai-platform-poised-to-transform-drug-discovery-and-pandemic-preparedness/